# Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

> **NCT05225831** · EARLY_PHASE1 · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- CD19+ and CD 22+ B-ALL

## Interventions

- **BIOLOGICAL:** Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
- **DRUG:** Cyclophosphamide,Fludarabine

## Key facts

- **NCT ID:** NCT05225831
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-15
- **Primary completion:** 2023-08
- **Final completion:** 2023-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225831, "Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05225831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*